Hello everybody and welcome back to Sounds of Science, a series of podcasts hosted by

Yukop, a European trade body representing small and mid-sized companies active in health

technologies.

My name is Stefan Romanolli and I am the senior government affairs manager at Yukov.

I will be your host for this episode.

Before moving forward, we'd like to kindly ask you to click on the subscribe button for our podcast and follow us on Twitter and LinkedIn to stay up to date on all of the latest news and initiatives

within the world of European life sciences.

On today's episode, we will talk about the revision of the general pharmaceutical legislation.

We will discuss the reports adopted on 10 April by the European Parliament,

less than a year after the Commission's proposal was released.

We will focus on two aspects specifically,

the incentives framework and the regulatory provisions.

Not only we will discuss the proposals adopted by the Parliament,

but we'll compare them with the Commission's approach.

We'll also share our thoughts on how the revised framework

might impact small and mid-sized companies and their investments in innovative treatments in Europe.

The guests of these episodes are my colleagues Victor Martens, Eukops' Government Affairs Director,

and Sean Byrne, Eukops Senior Manager Legal and Regulatory Affairs.

Welcome, Victor and Sean.

Onus et cetera.

Let's jump right in.

The revision of the general pharmaceutical legislation will bring many important changes to both the incentives framework and the regulatory ecosystem.

...